The Warriors will open talks with Brisbane about a suitable replacement player for Mitchell Barnett, after the State of Origin prop agreed to terms with the Broncos.
After requesting a release from the Warriors at year’s end on personal grounds, Barnett is set to link with the reigning premiers on a two-year deal from 2027.
There is also a mutual option for a third year in 2029, if both the Broncos and Barnett wish to continue his stay.
Barnett’s deal offers Brisbane a ready-made replacement for Payne Haas, after the star front-rower’s shock defection to South Sydney for next season.
It comes after Barnett had declared he wanted to move back to Australia for his son’s medical treatment, with family on the NSW mid-north coast in Taree.
Parramatta and Manly had also been in contention for Barnett’s signature, with the 31-year-old having spoken to both clubs before opting to prioritise the Broncos.
In order for Barnett to officially be released by the Warriors, the Auckland-based club will want a player in return.
“Everyone is aware of that. We are waiting to understand what that could look like,” Warriors CEO Cameron George told AAP.
“I am not going to name names. We are in talks with Brisbane and waiting to hear back from them.”
After leaving Newcastle at the end of 2022, Barnett has developed into one of the best front-rowers in the competition.
At the same time, the volume of top-tier props has decreased, making him one of the most valuable commodities on the market for 2027.
George said the Warriors had always put Barnett’s welfare at the forefront when agreeing to release him, but they also require playing talent from Brisbane so they are not disadvantaged.
“The most important thing since Mitch and I had the conversation was that it is all about him and his family,” George said.
“The decision from then on was for Mitch to make and not for us.
“Equally we are waiting to understand what the transaction looks like but I am extremely happy for Mitch and his family.”
Airlines can take control of the payments experience for both direct and in-direct channels
Move improves cashflow and loyalty for airlines by directly processing UnionPay cards
SHANGHAI, March 12, 2026 /PRNewswire/ — According to ResearchAndMarkets’ recent forecasts, Chinese outbound travel is predicted to grow at a Compound Annual Growth Rate (CAGR) of 13.5%, increasing from $140B today to reach $386B by 2033. UnionPay International helps cardholders to easily make cross-border payments in 183 markets and its payment methods are particularly popular with travelers across Asia Pacific. That’s why being able to directly accept UnionPay cards is crucial for airlines serving travelers from the 85 countries and regions where UnionPay cards are issued.
Under the terms of a new partnership between Outpayce from Amadeus and UnionPay International, airlines that power online payments in their direct channels with Outpayce’s Xchange Payments Platform can natively accept UnionPay cards in the standardized way. This native acceptance secures more revenue for airlines while improving the payment experience for travelers by drastically increasing acceptance rates.
The Amadeus Travel Platform is a comprehensive marketplace connecting travel providers like airlines, hotels, car rentals and rail operators to more than 60,000 travel sellers so they can combine and retail attractive offers. Thanks to the new partnership, travelers wishing to pay with a UnionPay card can be passed through to the provider to pay directly when making a booking.
The new approach means travelers can access the same payments experience as an airline offers on its website, including access to loyalty benefits that depend on making payment directly with the airline.
By directly processing the payment, airlines improve cash flow by accessing funds faster and can also take control of the payments experience for indirect bookings. By applying their own approach to issues like fraud management, airlines can improve acceptance rates and deliver a better overall experience.
Bomme Sheng, Global Director of UnionPay International said: “UnionPay has established a solid presence in the airline payment vertical. By deepening cooperation with Amadeus, UnionPay cards will be fully integrated into the underlying technology of airline distribution, covering websites, and indirect channels. This will further refine UnionPay’s air travel payment ecosystem and promote the industry to upgrade towards greater efficiency and diversity.”
Damian Alonso, Head of Product and Partnerships, Outpayce said: “We are committed to enabling a smooth payment experience in every channel however the traveler chooses to pay. Our payment platform approach means travelers can pay with the method of their choice in a way that’s easy and trusted. Airlines can now offer the same payments experience to UnionPay cardholders whether they are shopping via Amadeus travel sellers or in their own direct channels, maximizing investments in payments and improving the overall experience.”
The addition of card acceptance for UnionPay means that travelers can pay travel providers directly with all major card schemes when their booking is completed via the Amadeus Travel Platform. Native acceptance of UnionPay cards via the Outpayce Exchange Payments Platform is expected to be enabled in H1 2026 and will be enabled gradually across different markets throughout 2026 within the Amadeus Travel Platform.
Left to right: Larry Wang, CEO of UnionPay International; Dong Junfeng, Chairman of China UnionPay and UnionPay International; Luis Maroto, President and CEO, Amadeus; Sam Abdou, CEO, Outpayce from Amadeus
Notes to the editors:
About UnionPay International
UnionPay International (UPI) is dedicated to expanding UnionPay’s global network and building seamless cross-border payment experiences. In partnership with over 2,600 partners worldwide, UPI enables card acceptance in 183 countries and regions with issuance in 85 countries and regions. UnionPay International provides high quality, cost effective and secure cross-border payment services to the world’s largest cardholder base and ensures convenient local services to a growing number of global UnionPay cardholders and merchants.
About Outpayce
Amadeus makes the experience of travel better for everyone, everywhere by inspiring innovation, partnerships and responsibility to people, places and planet. As a wholly-owned company, Outpayce from Amadeus is the next step in scaling the Amadeus payments business with fresh investment in talent, an open API platform and a license to deliver new regulated payment services.
Outpayce delivers smoother end-to-end travel experiences making travel payments simple. Our open platform connects FinTech and banking service providers to the entire travel ecosystem, allowing customers and travelers to easily benefit from new advances in payments.
Outpayce Xchange Payment Platform (XPP) solves challenges in areas like authentication, acceptance and foreign exchange (FX) for travel merchants and gives access to partners that resolve areas like fraud management and authentication to offer a smoother overall experience for the traveler.
In the B2B payments space, Outpayce orchestrates payments with a range of virtual cards, currencies and payment methods to optimize cost, acceptance and agility wherever a travel seller needs to pay a supplier.
Outpayce delivers an end-to-end experience by continuing to work with all Amadeus’ teams and embedding its capabilities in all of Amadeus’ applications. The future is travel simply paid.
The aircraft had just departed Newark Liberty International Airport Monday morning, March 9, and was bound for Jacksonville, Florida, when the strike happened.
The airline confirmed the incident to Fox News Digital.
“United flight 1207 safely returned to Newark following a bird strike,” according to a United Airlines statement shared with Fox News Digital.
The FAA said the flight crew indicated the windshield had been cracked and that there may have been a problem with cabin pressurization after the bird strike.(Gary Hershorn/Getty Images)
The FAA tracks reported wildlife collisions through its Wildlife Strike Database, which has collected data since 1990, the FAA website noted.
Reporting is voluntary, so the numbers reflect incidents submitted by airlines, pilots and airports.
Federal data shows that roughly 291,600 wildlife strikes involving civil aircraft were reported in the U.S. between 1990 and 2023.
In 2023 alone, nearly 19,400 strikes were recorded at more than 700 U.S. airports.
The FAA has said the increase in reported incidents is linked to rising wildlife populations, more aircraft traffic and improved reporting.
The agency continues to expand research and mitigation efforts to reduce risks near airports.
More than 700 airports across the United States reported nearly 19,400 wildlife strikes in 2023 alone.(iStock)
Fox Business previously reported on a separate United Airlines incident involving windshield damage last year.
In that case, a United Boeing 737 Max 8 traveling from Denver to Los Angeles diverted to Salt Lake City after the crew discovered a crack in the aircraft’s multilayer windshield at a cruising altitude of 36,000 feet.
Max Layton, Citi global head of commodities research, joins ‘The Exchange’ to discuss the IEA’s decision to release barrels of oil, which parts of the energy complex will remain under pressure and much more.
WUXI, China, March 12, 2026 /PRNewswire/ — LabConnect, a leading provider of technology-driven central laboratory services and functional service provider solutions for clinical trials, today announced the grand opening of its new facility in Wuxi, China. As clinical trials become increasingly global and complex, sponsors are seeking laboratory partners that can provide integrated testing, logistics and data oversight across regions. Together with LabConnect’s laboratory capabilities in Australia, the new site strengthens the company’s ability to support multi-regional clinical trials while helping Asia-Pacific pharmaceutical, biotechnology and clinical research organizations expand their research programs globally.
Fully integrated into LabConnect’s global infrastructure, the Wuxi facility enables study teams to operate across regions with unified data, consistent operational oversight and advanced sample logistics and handling procedures.
The facility was developed in collaboration with Teddy Laboratory, now part of Frontage Laboratories, combining Teddy Laboratory’s local laboratory expertise with LabConnect’s global central laboratory services, logistics capabilities, and technology-driven decentralized network model.
“This facility reflects LabConnect’s continued investment in building the global services needed to support clinical trials today and the next generation of clinical research,” said Wes Wheeler, Chief Executive Officer of LabConnect. “We are proud to offer China-based capabilities and a global service network that supports both multinational pharmaceutical and biotechnology companies entering China and Chinese companies expanding into international markets.”
The Wuxi facility will support a range of clinical trial services, including custom kit building, advanced sample tracking and logistics, and biorepository services, all designed to meet international regulatory standards.
The grand opening event, held today at the facility in the Xinwu District of Wuxi, included a ceremonial ribbon cutting, guided laboratory tours and presentations highlighting LabConnect’s technology-driven approach to central laboratory services. Representatives from LabConnect, Teddy Laboratory, government officials, and members of the regional clinical research community attended the event.
With the addition of the Wuxi site, LabConnect now operates eight global locations, enabling sponsors and CROs to rely on a single partner for central laboratory services across studies of any size or geographic complexity.
About LabConnect LabConnect is a global provider of technology-driven central laboratory services and functional service provider solutions for pharmaceutical, biotechnology and contract research organizations. The company connects laboratories, logistics, technology and scientific expertise through a decentralized laboratory network model to deliver integrated solutions for clinical trials worldwide. Learn more at www.labconnect.com.
NYSE issues a pre-market daily advisory direct from the trading floor.
NEW YORK, March 11, 2026 /PRNewswire/ — The New York Stock Exchange (NYSE) provides a daily pre-market update directly from the NYSE Trading Floor. Access today’s NYSE Pre-market update for market insights before trading begins.
Entrepreneurs First to join Taking Stock after the market close
Kristen Scholer delivers the pre-market update on March 11th
Equities remain choppy as the conflict in the Middle East continues and the International Energy Agency is proposing the biggest-in-history release of emergency oil reserves.
Inc. unveiled its 2026 Female Founders 500 list yesterday, honoring dynamic women business leaders.
Entrepreneurs First announced earlier that it raised $200 million to support the next generation of builders, with contributions from investors including Reid Hoffman and Eric Schmidt.
U.S. Antimony (NYSE: UAMY) Chairman and CEO Gary Evans will join NYSE Live this morning to explain the company’s critical role in defense applications.
Opening Bell U.S. Antimony (NYSE: UAMY) celebrates its uplisting to the NYSE
Closing Bell Costamare Bulkers (NYSE: CMDB) celebrates its 2025 spin-off
For market insights, IPO activity, and today’s opening bell, download the NYSE TV App: TV.NYSE.com
Bunge CEO Greg Heckman hosted its investor day at NYSE
Capital gains tax (CGT) is gaining plenty of attention again as concerns about the cost of housing force the federal government to lay its cards on the table and contemplate where to make changes before the upcoming budget.
First introduced in the 1980s to impose tax on capital gains, it applies tax on the profit made when selling or disposing of an asset. It means your net capital gain is taxed at the same marginal rate as your regular income.
Then in 1999, the CGT discount was introduced. This change was designed to simplify the system, applying a 50 per cent CGT discount instead.
Since then, house prices have soared to unaffordable levels for many Australians.
While it applies to a range of investments including shares and crypto assets, the way that CGT is applied to property is top of mind for government decision-makers right now.
What are the options
One of Australia’s leading public policy economists, Professor Robert Breunig, from the Australian National University, is adamant that the change being considered could result in lowering the CGT.
This could be done by dropping to a fixed discount rate less than the current 50 per cent – say 45 per cent, or 40 per cent, he says.
Or, Treasury could switch to calculating the actual inflation rate that occurred during the life of the asset and discounting the CGT by this amount, he says.
There are many reasons that people invest in property and changing the CGDT will make investor properties slightly less attractive. Pic: Shutterstock Credit: View
This method would be the better way of adjusting for the inflationary component of the growth in the value of the asset, but a fixed number is easy for people to understand.
“Treasury is considering whether to change CGT discount only for investor properties or for all assets,” Professor Breunig said.
“Doing it for all assets would be preferable so as not to bias savers towards different forms of savings but if the government wants to send a signal to people that they want them to invest in other assets, and not property, then only lowering the CGTD on investor properties would be consistent with this message.”
Whether or not the changes will be grandfathered is what will impact investors the most, he says.
“Not grandfathering will mean that the benefit of a higher CGTD is “locked in” for older, wealthier people and not available to younger, less wealthy people,” Professor Breunig said..
“In this sense, not grandfathering would make inter-generational equity worse, not better. This is a major concern.”
Regardless of how changes are rolled out, Professor Breunig doesn’t believe it will have a significant impact on the property market more broadly.
“There are many reasons that people invest in property and changing the CGDT will make investor properties slightly less attractive. This would mean some shift towards more homeowners and less investors in the property market.
“Most sensible models also suggest that it would lead to higher rental prices for those who do not buy a property. But all of these changes would be pretty small. The big issue in housing is supply, particularly in the big cities where everyone seems to want to live,” Professor Breunig says.
In the meantime, investors are holding their breath in the lead-up to the May 2025 Federal Budget, which is when potential reforms are expected to be announced.
ROME, March 11, 2026 /PRNewswire/ — Haier Biomedical recently convened its European Partner Summit in Rome under the theme “Advancing Together – Sharing the Future of Biomedical Innovation,” which brought together 37 regional partners and industry leaders from 23 European countries to outline its long-term commitment to Europe and unveil a broadened laboratory solutions portfolio, marking a strategic upgrade of its brand portfolio. New strategy shifts toward scenario-based, application-driven solutions, while sharing its long-term plan to deepen localization in Europe and deliver more comprehensive, tailored services and support across the region.
Haier Biomedical, Intelligent Protection Of Life Science
Haier Biomedical Hosts European Partner Summit in Rome and Advances “In Europe, for Europe” Strategy
At the summit, Enrique Wang, Global Market Director of Haier Biomedical, reaffirmed the Company’s global vision to achieve over 50% of global revenue from international markets by 2027 and over 50% revenue contribution beyond refrigeration by 2028. He emphasized that Europe remains a strategic priority within the company’s globalization roadmap, which underscores the “In Europe, for Europe” localization principle of delivering products, services, and support tailored for regional regulatory standards, customer expectations, and application needs.
Outlining the 2026 European strategy, Semir Selimovic, director of North, Central & Eastern Europe of Haier Biomedical Europe, highlighted continued investment in local sales, service, and product expertise to strengthen responsiveness and execution across key markets. Europe has become one of Haier Biomedical’s fastest-growing international regions, and this is supported by expanding local teams and a steadily broadening product portfolio.
Expanding from freezers to full solutions
Among the newly introduced products, the Plasma Apheresis System XJ-III drew particular attention. The system has obtained EU MDR certification, which marks a significant milestone in meeting Europe’s stringent regulatory requirements and strengthens Haier Biomedical’s position in blood and plasma technology. Across Europe, Haier Biomedical’s CO₂ incubators, centrifuges, biosafety cabinets, and cold storage lines continue to gain market share, supported by energy-efficient technologies and compliance with regional certification standards. The product evolution presented in Rome demonstrates a move toward unlocking a full portfolio capable of supporting laboratories, hospitals, and life science institutions with end-to-end solutions.
Automation and intelligent blood management as growth engines
Daniele Pericolini, European Automation Solution Specialist of Haier Biomedical, outlined the Company’s strategy to drive future growth through laboratory automation and intelligent blood management systems. Haier Biomedical’s automated biobank solutions integrate RFID-enabled ultra-low temperature storage, modular automation platforms, and liquid nitrogen systems to enhance sample traceability and operational efficiency. By addressing challenges such as sample integrity, temperature tracking, and high-density storage, the Company has positioned itself within Europe’s growing demand for advanced biobanking infrastructure.
Additionally, the U-Blood intelligent blood management system represents a shift from traditional cold storage to real-time connected blood supply chain management. Designed to reduce wastage, improve traceability, and support round-the-clock transfusion workflows, the solution aligns with Europe’s increasing focus on safety, digitization, and zero-waste healthcare initiatives.
European customer recognition and brand alignment
The summit also featured success stories from four European partners representing Germany, Slovakia, France, and Denmark, which highlighted strong local validation of Haier Biomedical’s solutions. In France, long-term partner showcased the jointly developed biosafety cabinet adapted to French standards, with over 230 units deployed across over 100 customers. In Denmark, Haier Biomedical partner shared its ultra-low temperature freezer success through public tenders and ongoing expansion into additional product categories. In Slovenia, large-scale pharmaceutical installations reinforced the Company’s capabilities in managing complex, multi-unit projects. Partners from Central Europe also emphasized reliability, regulatory compliance, and after-sales support as key differentiators.
Strong international growth performance in 2025
Haier Biomedical’s expanding European footprint is supported by a solid financial performance. In 2025, the Company reported revenue exceeding RMB 2.3 billion, with international revenue reaching RMB 840 million, which accounts for over 36% of total revenue and reflects continued global expansion.
Europe recorded double-digit growth, which contributed to a large portion of overall international revenue growth. The Company’s AI-driven and automation-related solutions contributed approximately 15% of total revenue in 2025, which signalled accelerating technology-driven transformation. These results reflect a broader shift from hardware exports toward localized solution delivery supported by regional teams and certifications across over 18 countries.
As the European Partner Summit concluded, Haier Biomedical reaffirmed its commitment to strengthening localized operations, expanding automation and life science solutions, and advancing collaborative growth with partners. Through a combination of global innovation capabilities and local execution in Europe, the Company aims to further consolidate its position as a trusted life science solutions provider in 2026 and beyond.
The United Arab Emirates (UAE) has been targeted by Iranian missiles at airports, tourist hot spots, the U.S. consulate and other hubs, posing serious threats to travelers.
Now, British Airways has announced it will be suspending its services to Abu Dhabi until the end of the year while canceling other destinations for the rest of the month.
“Due to the continuing uncertainty of the situation in the Middle East and airspace instability, we’ve had to temporarily reduce our flying schedule in the region,” the airline announced in a statement on X.
All flights to and from Amman, Bahrain, Doha, Dubai and Tel Aviv have been canceled until later this month, the airline said.
“We’re keeping the situation under constant review and are in touch with our customers to offer them a range of options,” the announcement continued.
The Zayed International Airport states on Abu Dhabi’s website that “passengers are advised not to travel to the airport unless they hold a confirmed ticket and have been explicitly advised by their airline to do so.”
It also says, “Access to the airport will be restricted to confirmed travelers only.”
On Saturday, a Dubai Airports spokesperson announced a “partial resumption of operations with some flights operating out of Dubai International (DXB) and Dubai World Central – Al Maktoum International (DWC).”
Airports in the UAE are restricting access to travelers only. (Altaf Qadri/AP Photo)
“Travelers are urged to not travel to the DXB or DWC unless they have been contacted by their airline that their flight is confirmed, as schedules continue to change,” the announcement says.
The latest announcement continued, “Dubai Airports continues to closely monitor the situation in coordination with relevant authorities, and our focus remains on maintaining the highest standards of operational safety, security and well-being of passengers and staff.”
On Abu Dhabi’s website, the Zayed International Airport (pictured) states that “passengers are advised not to travel to the airport unless they hold a confirmed ticket and have been explicitly advised by their airline to do so.”(Nicolas Economou/NurPhoto via Getty Images)
Lufthansa Airlines has suspended flights to and from Dubai and Abu Dhabi until March 15 and Dammam until March 15, according to its site.
Virgin Atlantic announced that its “Dubai service is suspended for the remainder of the winter season.”
“Dubai is a seasonal route for Virgin Atlantic and was due to conclude on 28 March; however, the recent escalation in the Middle East has brought forward the end of our operation for this season,” Virgin Atlantic’s website states.
The State Department has facilitated the safe return of many thousands of American citizens from the Middle East since Feb. 28. (Ryan Lim/AFP via Getty Images)
Flights to and from Dubai are suspended until March 28.
As of Saturday, Emirates has resumed operations, according to its X account.
A State Department spokesperson told Fox News Digital earlier that the department had facilitated the safe return of over 20,000 American citizens from the Middle East since Feb. 28.
That number was updated Tuesday. As of Tuesday, 40,000 American citizens have safely returned to the U.S. from the Middle East since Feb. 28, the department said.
Ashley J. DiMella is a lifestyle reporter with Fox News Digital.
BEIJING, March 10, 2026 /PRNewswire/ — Beijing Tsingke Biotech Co., Ltd. (“Tsingke Biotech“) and iGeneTech Bioscience Co., Ltd. (“iGeneTech”) have announced a strategic partnership aimed at advancing the field of synthetic biology. This collaboration brings together the strengths of both companies to drive innovation, streamline product development, and expand market reach.
The partnership was formalized at a signing ceremony held at Tsingke Biotech’s Beijing headquarter, where both companies expressed their shared commitment to revolutionizing synthetic biology in response to the growing needs of the market.
Harnessing Expertise to Transform the Industry
Synthetic biology is rapidly emerging as a transformative field with wide-reaching applications, including precision medicine, bio-breeding, and gene editing. At the core of these advancements are high-throughput and column-based synthesis, which Tsingke Biotech and iGeneTech aim to further develop.
Tsingke Biotech, a leader in gene synthesis, has developed a fully integrated industrial chain that spans raw materials, equipment, process design, AI, and digital technologies. Known for its scalability, standardization, and stability, the company’s cutting-edge technology includes column synthesis and an intelligent factory-driven production system that supports from small-scale laboratory production (2nmol) to large-scale industrial synthesis (12mmol). Their gene synthesis services include:
Primer Synthesis (<300nt)
Gene Synthesis (300bp–5kb)
Long Gene Synthesis (>5kb)
On the other hand, iGeneTech contributes its proprietary Ignite 3.0 high-throughput synthesis platform. With its ability to process oligo pools ranging from 4k to 650k in size and achieve synthesis lengths up to 200nt with error rates as low as 0.2%, this platform addresses key challenges around throughput, speed, and cost.
A Shared Vision for Growth
“We are excited to partner with iGeneTech, whose expertise in gene capture and next-generation sequencing (NGS) technology enhances our strengths in gene synthesis,” said Mr. Shijin Ma, CEO of Tsingke Biotech. “This partnership will speed up the translation of technological innovations into real-world applications, helping drive the industry forward.”
Mr. Wanshi Cai, CEO of iGeneTech, added, “Tsingke Biotech’s integrated industrial chain and leadership in gene synthesis will be crucial in supporting our continued growth. Together, we will push the boundaries of synthetic biology and its potential across various industries.”
Both companies are committed to developing an integrated system that spans the entire spectrum from “synthesis” to “application,” focusing on innovation, sustainability, and precision to meet the needs of a rapidly evolving market.
About Tsingke Biotech
Tsingke Biotech is a leading innovator in synthetic biology, with a mission to build “the world’s great gene factory.” Combining proprietary reagents, consumables, and synthesis equipment with AI-driven molecular manufacturing technologies, Tsingke Biotech provides efficient and high-quality gene synthesis services. Its work supports industries ranging from biopharma to agriculture, food, and environmental sciences.
About iGeneTech
iGeneTech specializes in gene capture technologies and holds intellectual property in NGS probe hybridization, multiplex PCR, and high-throughput DNA synthesis. The company’s high-quality oligo pool synthesis capabilities enable the creation of precise and uniform sgRNA libraries for gene-editing applications, including genome-wide and target-gene sgRNA libraries, and off-target detection.
